This event has now reached its third birthday and is fast becoming an industry must attend show. Since 2015 the event is forecast to almost double in revenue.
The delegate campaign has been very successful in both 2015 and 2016, attracting a large number of attendees from South Korea, Japan, China, Taiwan and Singapore.
The clinical trial supply East Asia 2017 is due to take place on the 6th-7th of December 2017 in Seoul, South Korea.
This is the only event focusing Clinical Trials Supply in Korea. This event focuses on providing discussions to achieve efficient and seamless clinical supply for trials, as well as providing an In-depth overview into the key regulatory challenges faced by companies in the East Asia region. This is a unique event encompassing discussions around strategies to ensure smooth clinical trial supply chain
In addition to this, the event will look at a the newest innovations in clinical trial supply at an event that will bring together key professionals across different companies and combine the knowledge of both small, emerging the perfect opportunity for attendees to discuss with competitors, service providers and companies of different sizes the best ways to implement their strategy
Why This Event – Why Now?
The landscape of clinical trials in Asia is changing. Many of the global pharmaceutical companies may have first decided to move to Asia for the patient pool and cheaper cost. However, the whole spotlight in Asia is now impacting the pharmaceutical sector rather than just the mere clinical trials industry. Companies need to set their strategic sights on a future world where Asia is not just a market for the pharma industry, but could make a key contribution to drug discoveries as well.
Why CTS East Asia?
Asia now has more clinical trials than any other region in the world. Through research with suppliers there is some disagreement over whether the local market is growing in terms of companies, however no dispute at all in the number of trials happening in the region.
Why South Korea?
Despite much clinical activity, and certain evidence of growth in pharmaceutical industry in Asia, there are no clear signs of a compelling industry ‘cluster’ as seen in USA and Europe. Although, most countries in the region are making progress, and often with the support of the Government, few have reached the level of maturity necessary to be seen as a cluster.
For more information click here http://www.arena-international.com/ctseastasia/
To register click on the link and quote reference: MK-SP-AD